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Dr. S. Mitchell Harman is an internationally recognized expert regarding the effects of aging on
hormone regulation and the use of hormone therapy in older men and women. In 1999, Dr. Harman
became the first Director of the Kronos Longevity Research Institute in Phoenix, Arizona. Established
to conduct and foster transnational research, the Institute provides a critical link between findings from
the basic research laboratory and corresponding improvements in clinical care and human health. In
the following interview, Dr. Harman draws from his rich professional experience to provide a revealing
perspective on gerontology and related issues of aging.
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Dr. S. Mitchell Harman, Director of the Kronos Longev-
ity Research Institute, is an internationally recognized
expert on the effects of aging on hormone regulation
and the use of hormone therapy in older men and
women. Dr. Harman received both his Ph.D. and M.D. in
1970, graduating with honors from the 6-year com-
bined Medical/Graduate School program at the State
University of New York Downstate Medical Center.
Dr. Harman has trained in Internal Medicine at the
Yale New Haven Medical Center, in endocrinology at
the Reproduction Research Branch of the National Insti-
tute of Child Health and Human Development (NICHD)
of the NIH, and in gerontology at the NICHD Geron-
tology Research Center in Baltimore. In 1976, he founded
the NIA laboratory for the study of aging of the repro-
ductive hormone system in males and females within
the Endocrinology Section. While in Baltimore, Dr. Harman
joined the faculty of the Johns Hopkins University and
became a member of the attending physician staff of
what is now the Johns Hopkins Bayview Medical Center
(at that time, known as Baltimore City Hospital). From
1974 to 1999, when he retired as a Captain in the U.S.
Public Health Service, Dr. Harman rose to become the
Chief of the Endocrinology Section in the Laboratory of
Clinical Physiology, IRP, NIA. He also served as acting
Chief of the LCP and acting Clinical Director of the NIA
for nearly two years.
Dr. Harman was promoted to Associate Professor of
Medicine at the Johns Hopkins University in 1984. He
is board certified in both Internal Medicine and Endo-
crinology. He is the author or co-author of one book
and nineteen book chapters, many in major textbooks
of Medicine, Geriatric Medicine, and Endocrinology. He
has published 58 peer-reviewed papers and presented
numerous research reports at scientific meetings. Dr.
Harman is also the holder of 5 patents in the area of
controlled release drug administration. In 1995 he re-
ceived the Louis M. Hellman Master Teacher Award
from the Downstate Medical Center.
In 1999, Dr. Harman became the first Director of the
Kronos Longevity Research Institute. The Kronos Longevity
Research Institute was established to conduct and foster
translational research—the critical link between findings
from the basic research laboratory and corresponding
improvements in clinical care and human health. With
aims of preventing the common diseases associated
with aging, slowing the aging process, and prolonging a
vital, healthy human lifespan, the Kronos Institute dis-
seminates accurate scientific information (regarding novel
strategies for reducing the deleterious impact of the
aging process and age-related illnesses) to both the pro-
fessional and lay communities via publication, scientific
meetings and symposia, and the media.
How important are hormone changes in producing
some of the things that we attribute to aging—some of the
things that are responsible for a loss of function?
I have spent my research career up until now first
documenting which hormones change and how much
they change as people get older. This involves investi-
gating the mechanisms responsible for those changes in
some experimental systems in animals, and then, most
recently, looking at the effects of replacement hormones
in older people to see if some of the documented losses
in function that occur with age are really due to the hor-
monal changes. It is clear that altered hormone balance
does explain some of the changes in body composition
and function that occur with age, but this is far from
the whole story. Since I have taken on the Directorship
of the Kronos Institute, I have not been nearly as special-
ized because I now have a much broader mission. I
can't just limit myself to hormones. I have had to start
to think about aging as a whole and its effect on all of
the important systems that maintain health and life. So
my time here has involved a very steep learning curve.
I have learned a lot about many things that I really
didn't know very much about before, like oxidative
stress, cardiovascular disease, cognitive changes, and
other issues that really weren't on my plate at the National
Institute on Aging.
You may have already started answering this question,
but how did you get interested in studying aging?
I came to Gerontology, the study of aging, the way
most people in science get interested in one thing or
another. In 1964, when I graduated from Emory Uni-
versity with a Biology major, I was actually interested
in what is now called genomics, but at the time there
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wasn't any science of genomics. There was cytogenics;
people were counting chromosomes and beginning to
figure out which known genetic traits were carried on
which chromosomes. The methods were primitive, in-
volving examining stained spreads of chromosomes
under the microscope—to subdivide them by visible
bands and try to figure which traits segregated with
which bands. I went to the Downstate Medical Center
of the State University of New York at Brooklyn to
begin an MD, PhD program, thinking that I would do
work in genetics and cytogenics. If I had done that, I
would probably have been a full professor at Harvard
or Yale by now. Because, as you know, this has turned
into a very hot field. But when I got to Downstate there
wasn't anybody there working in cytogenetics, so I
couldn't find a major professor for my thesis in that
area. I wound up doing a reproductive physiology
project in the Anatomy Department because repro-
duction was about as close to genetics as I could get.
The Anatomy department, at that time, was very inter-
ested in aging as it affected the reproductive system.
My major professor, George Talbert, had done some
really groundbreaking work in terms of understand-
ing how the aging process affects ovarian function. And
what you do when you are a graduate student is what
your major professor is interested in. So I got into
aging.
/ have known you for a while and you seem to
know what the real questions are. The important
questions.
Boy, I wish that were true. I would like to think that
I know what some of them are, anyway.
What do you think are the important questions right
now in the field?
In aging?
Yes, issues and questions.
The really important questions have to do with the
mechanisms underlying the aging process and what
leads to the progressive, cumulative damage to cell com-
ponents which we call aging. A related question is why
our stem cells, which are present in many tissues, fail
to efficiently replace age-damaged, senescent cells with
new functional cells over time. The manifestations which
we can see, the aging phenotype, has been well known
for centuries—gray hair, sagging weakened muscles,
wrinkled skin, increased body fat. But, the processes
underlying these changes are just beginning to become
clear. We are starting to learn to measure the rate of
damage, distinguish the different kind of damage, as
well as which organs are being damaged most. We
now have some clues to where the chemicals that cause
this damage are coming from and how the repair systems
work to ameliorate, prevent, and minimize the damage.
When we fully understand those processes we'll (1)
know what aging really is and (2) have some very good
clues concerning what to do about it.
Is there anything on the horizon that supports these
indications?
Oh, absolutely. There are a number of very exciting
developments in aging. First of all, evidence continues to
accumulate that oxidative damage to cell components
(that is, to proteins, to the lipid in the cell's membranes,
and—importantly—to both nuclear and mitochondrial
DNA) is really at the heart of the aging process. I think
the evidence is so good now that many alternative
hypotheses are falling by the wayside. So, that line of
research is very, very important. The most exciting single
finding is that the life span has actually been extended
by as much as 50% in a variety of organisms, by what
is called caloric restriction. What these experimenters
do is to make sure that the animals get all of the nutrients
that they need to survive—enough protein, enough vita-
mins, enough minerals—but the absolute number of
calories is cut to 35-40% below what they would con-
sume if allowed to eat all they wanted (ad libitum
feeding). What happens in these animal models, whether
it is fruit flies, or round worms—those little Caenor-
habditis elegans, that the worm runners love so much,
or mice and rats which, compared to the first two species
are very close relatives of ours—is that all of the changes
that would be associated with aging in those animals
(and, of course, the manifestations differ in different
species) are delayed. For example, in the mice—one of
the things that happens with age, just as it does in humans,
is that the cancer rate goes up. Mice only live about
two and a half years. In mice that are 15 to 18 months
old, you see a big increase in cancer. Well, if you
calorie restrict those animals, the cancer rate goes up
but it goes up much later. They die at over 3 years of
age. The whole aging process gets stretched out. At 2
years those animals still look young. They are vigorous,
whereas the ad lib fed animals look old and sick—they
are dying. So, what this suggests is that the aging process
is modifiable. That it is not inevitable. That there is not
a limit to the life span that can't be moved.
What is really exciting about this work (because,
obviously, most people are not going to restrict their
calories by 40% from the age of 15 or 16 years) is that
there are some agents which seem to imitate some
aspects of what caloric restriction does and also reduce
oxidative damage. I think that in the near future there
may be candidate drugs which can be tested, that will
act like caloric restriction at least partially, and reduce
the rates of aging damage.
One theory as to why caloric restriction reduces the
rate of damage is that if you have less energy to burn—
that is, less available fuel to burn—the mitochondria (the
little energy factories in our cells that provide the cell
with energy in the form of adenosine triphosphate—
ATP) become more efficient. Mitochondria combine
carbon fragments from fats and sugars with oxygen, in
order to produce ATP. However, mitochondria leak
what are called oxygen free radicals, such as super-
oxide, which combines with water to form another
toxic compound, hydrogen peroxide, and other very
reactive molecules. These highly reactive compounds
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damage a variety of cell components. Mitochondria that
are on a restricted diet may become more efficient. This
may be because certain mitochondrial genes become
more, or less, active. The mitochondria don't leak as much
oxygen free radical and therefore the whole aging
process gets slowed down. Also, defense mechanisms
that detoxify oxygen radicals may be up-regulated. In
fact there are new agents which act like the enzymes
that intercept and detoxify the oxygen free radicals.
These enzymes are called SOD (superoxide dismutase)
and catalase. There are now drugs that act like SOD and
catalase. They get into the cell and break down super-
oxide into harmless oxygen and water.
That is one of the questions I wanted to ask you and
you have gotten into it. What do you think about the
anti-aging drugs and herbs, including anti-oxidants,
that are on the market? Do you believe that they are
effective?
I'll come back to that, but first, I do want to mention
that there is another really important development in
understanding aging that is different from oxidative
stress, and that is the telomere hypothesis. This interesting
mechanism of aging that still needs to be worked out
has to do with what is called the Hayflick phenomenon.
Dr. Leonard Hayflick discovered that if you culture
normal cells—not cancer cells, but just normal healthy
fibroblasts from skin—they will divide a certain number
of times in the culture dish and then stop. These cells
are said to undergo replicative senescence because
they won't divide anymore. It turns out that the likely
reason for this is that every time cells divide, some little
structures called telomeres at the end of their chro-
mosomes get shorter. When they shorten beyond some
critical limit, the cell gets a message to stop dividing.
Most normal somatic cells—that is, body cells—lack an
enzyme called telomerase that extends the length of the
telomeres. Germ cells, which are immortal (if you think
about it, we're descended endlessly from a chain of
immortal—so far—living cells, back to the dawn of life),
extend their telomeres whenever they divide. Other
cells that do this are most kinds of cancer cells. So, they
are immortal too. The telomerase story, I think, is going
to be very important in understanding aging. How we
put oxidative stress and the telomere/Hayflick phe-
nomenon story together will probably give us the key
to how aging really works. I would say that the caloric
restriction experiments, the understanding of oxidative
stress, and the telomere story are probably the most
important developments in aging right now.
Do those relate to antioxidants?
What most antioxidants do is to act as substitutes for
cell components that might otherwise be damaged. They
"sacrifice" themselves by becoming oxidized and they
use up the oxygen free radicals. Therefore the oxygen
free radicals don't damage the cell components because
they run into vitamin E or vitamin C, or whatever anti-
oxidant they encounter first. They expend their fury on
the antioxidant, after which they are harmless. In fact,
we have a lot of natural antioxidants in our cells, includ-
ing these vitamins, as well as systems for reducing and
regenerating our natural antioxidant molecules, such
as glutathione. Without these natural antioxidants, we
would probably age a lot faster. We also have several
different enzyme systems that can detoxify oxygen free
radicals and repair oxidative damage. The problem is
that none of these mechanisms is perfect. None of them
are 100% effective. So, some of the oxygen free radicals
get through and damage the cell components and some
of this damage goes unrepaired. So, it accumulates
over time.
Is this what aging does? Is this what is meant when
we read about research on "slowing down aging" or
"reversing" the aging process?
Well, that is what we think. That is the theory. And
I think the evidence is pretty good for that now.
What I am hearing—and I'm not sure that I am
understanding the level of what you are saying—is that
maybe we can retard some of the aging process. Diet,
caloric intake, and the antioxidants may help, and I have
heard that researchers may be developing drug enzymes
that will extend life.
The problem is that the antioxidants we have ex-
amined to date—things like vitamin E, CoQ-10, and
others—are not very effective. They don't seem to di-
minish the rate of damage very much. The reason,
probably, is that our cells are already pretty good at
detoxifying free radicals. There is a very delicately regu-
lated system in place to do that. So, if you add a lot
of vitamin E and you reduce the amount of free radical,
the enzyme systems—such as SOD and catalase, which
are responsible for going after free radicals—get the
message that there is not much free radical around
and, therefore, down-regulate, resulting in no net gain
in oxidative protection. So, we need more effective
interventions.
We need ways to up-regulate those enzymes or imi-
tate those enzymes. We need antioxidants that are much
more powerful than the ones we have. Basically, all the
things that are being sold right now with claims that
they extend life span, don't...There is not a bit of evi-
dence that any of them extend life span. In humans or
in any animal model.
/ read something just recently about vitamin E that
goes along with what is being said, that one should not
take more than 800 units of vitamin E and that it
actually decreases its anti-oxidant qualities.
That is right, it makes things worse, and vitamin C
is even worse in this regard. Vitamin C in high doses
actually becomes a pro-oxidant. Low levels of vitamin
C act as an antioxidant, high levels may become toxic.
They have the exact opposite effect from the one de-
sired, increasing the rate of oxidation. A normal vitamin
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C dose is somewhere around 100 mg. More than that
is probably not helpful. I think that at over 400 mg/day,
adverse and unintended consequences may occur.
One of the things in the literature that is confusing
to me is the difference between slowing down aging and
reversing aging. Are we really ever reversing aging or are
we just slowing it down?
Actually, there is one intervention, which I haven't
mentioned yet, that may "reverse" aging changes. This
other intervention affects what is called glycation cross-
linking, which is probably another important mechanism
of aging. It is a process different from, but related to,
oxidative stress. It is due to glucose molecules which,
like oxygen free radicals, are also very reactive, sticking
to proteins and linking them together. This process of
cross-linking is thought to cause stiffening of tissues
and membranes, etc. The cross-links accumulate with
age and this process alters or impairs protein function.
You can't easily get rid of cross-links either, because
they can't be broken by protease enzymes that would
normally clean up the damaged protein. So, you are
stuck with them. The cross-linked molecules are called
advanced glycation end products, or AGE's. These AGE's
may play crucial roles in some of the clinical manifes-
tations of the complications of diabetes mellitus, a
disease which in some ways has been described as an
acceleration of aging. There is a new family of drugs that
actually break the AGE cross-links. They are called AGE
breaker compounds. This is another very exciting de-
velopment.
I think when we really understand this whole busi-
ness, some combination of antioxidant compounds will
either stimulate or emulate the enzymes that break
down the oxygen free radicals, perhaps some agent that
stimulates repair processes, and the AGE breakers will
be used to promote longevity. It will be a cocktail of
different strategies that, put together in the right pro-
portions, will slow the aging process. But, to truly reverse
the process, no, I would be very surprised. That would
require a different order of intervention, something on
the order of genetic engineering, replacement of stem
cells, replacing the damaged tissues, essentially cell by
cell. That kind of intervention is not out of the question,
but not on the near horizon either, in my opinion.
By definition then, one could believe the AGE break-
ers may be reversing aging at some level.
Yes, reversing a small part of the aging process.
You may have answered this already, but what do
you think is the most significant achievement in aging
research, you indicated...
I've already mentioned the Hayflick phenomenon
and the discovery of telomeres and telomerase and the
experiments with caloric restriction. I think those are
probably the most significant things going on. And
actually there is an experiment going on at the NIA
right now, and one other center, looking at caloric
restriction (CR) in primates. We know CR works in mice
and fruit flies and a number of other animals, but it has
never been tried up until now in a really close relative
of ours. And it looks as if (although it is too early to say
for sure), it looks as if it is going to work in monkeys.
The indication we have is that the monkeys have now
reached the age where the cancer rate should go up
and in the ad lib fed monkeys it is going up. But, in the
caloric restricted monkeys there are many fewer can-
cers. So, we don't know yet if CR is going to work,
based on mortality rate. But, the cancer rate looks very
suggestive.
Do you think that would hold in humans?
It probably will, but I can't imagine most people—
there actually are people out there doing CR on them-
selves. There are fanatics who are out there restricting
their calories. But, the problem is whether they are
getting adequate nutrition. I suspect that a lot of them
aren't doing a very good job of it. They are trying to live
on lettuce and their immune system may be subnormal
or malnourished. They could become more vulnerable
to infectious diseases, among other problems.
They may not die of cancer, they may die...
They may die of infectious disease, or something else,
instead. It is very hard to get adequate nutrition, enough
protein, and enough vitamins and minerals and certain
other nutrients, while trying to live on cabbage and
string beans.
You may have answered this. Is there a biological or
genetic upper limit to how long we can expect to live?
What are the significant factors that contribute to life
expectancy, and if you could, name them and maybe
rank order them?
You know that life expectancy is a funny business. It
depends on what you mean by life expectancy. Every
species has what is called a maximum lifespan potential,
or MLP, which is species specific and, hence, must be gen-
etically determined. There has never been a 90 year old
dog and there probably never will be, because dogs have
a maximum life span of 25 years or so. Actually, that varies
also with the breed of dog. So we know that genes deter-
mine maximum life span because it is species specific
and varies predictably, even within different strains of the
same species. That last animal in any birth cohort, no
matter how well you treat it, dies at a certain age. For mice
(for most strains of mice), MLP is 2 to 3 years. For Chi-
huahuas it's up to 25 years. For horses, maybe 30 years.
For man it is something, just a little over 100 years. There
are few outliers that get to 110 or so, but absolutely no-
body gets much past that. So we humans have a genetically
determined MLP and right now we have absolutely no
intervention, except for caloric restriction, which hasn't
been tried in humans—which can extend the maximum
life span. But when you talk about life expectancy, that is
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a separate issue. What we really mean is how many years
an individual can expect to live. And the average life
expectancy has been increasing over the centuries.
But if you want to know how to extend your life ex-
pectancy, the answer is better nutrition, wearing your
seatbelt, keeping your blood pressure under control,
and a whole bunch of other common-sense things that
we know will reduce the risk of chronic diseases that
are the major causes of death in western society. It is
clear that eating lots of fruits and vegetables, and es-
pecially cruciferous vegetables—the cabbage-related
vegetables—decreases your risk of getting cancer. If
you think about it, most people die prematurely of heart
disease or cancer. If you exercise regularly, eat cor-
rectly, don't take risks like jumping out of airplanes,
etc., you are going to extend your life expectancy.
Control your lipids, control your blood pressure...These
are all things that we know work. But, you haven't ex-
tended the maximum life span potential by doing these
things. What you have done is improve the probability
that you will get closer to that maximum potential.
Genetic factors also affect life expectancy. Centenarians
tend to run in families, so it would seem that there are
people who just have "good genes." They probably have
better DNA repair processes, better antioxidants, better
whatever it is that slows the aging process. Because, after
all, if you think about it, we evolved from shorter-lived
ancestors, truly shorter-lived ancestors. Our line di-
verged from the common ancestor we share with the
chimpanzee about 4 million years ago. Chimps live to be,
on average, 48 or 50 years old—substantially less than
humans. Evolution has changed our genes over the last
4 million years and we have increased the chimpanzee
lifespan. So, it isn't surprising, given the variation in
genetic complements in the population, that some people
probably have genes that are better at improving life
spans than others. This is part of the explanation why
some people die of old age at 80 and some people die
of old age at 110. If you don't get any of the age-related
diseases you are still going to get old. The question of
how old you will get before you wear out is probably
settled by genes.
One of the things I think you implied just now relates
to my next question. I want to get an estimate of what
you think is most important, or least important, in help-
ing one reach their maximum. But I think you are
saying...
I'm saying that if you can avoid heart disease and
cancer, you have a much better chance. The way to avoid
heart disease is to stay lean, to exercise, to eat a diet
which is low in saturated fat which eliminates trans
fats, eat lots of fish which contains plenty of omega-3
fatty acids, and eat lots of fruits and vegetables, which
also help reduce cancer. Then, of course, there are other
standard things that you can do to reduce your risk of
cancer. The big killers are lung cancer (so, don't smoke),
breast cancer (so, women should get mammograms every
year, because if you catch breast cancer early, you prob-
ably won't die of it), and prostate cancer in men (so,
again, getting a PSA every year after the age of 50 is a
good idea). Then there is colon cancer—a lot of that
can be prevented by getting a colonoscopy over age 50.
There are other medical things that you can do to im-
prove your chances, such as controlling blood pressure.
And if your lipids are high, we have these wonderful
statin drugs now. A statin and Niacin can get almost
anybody's lipids into the normal range, unless they have
a serious genetic disorder.
Don't they affect things like the liver?
No, the new ones have almost no effect on the liver.
Liver toxicity is the big bugaboo that everyone is worried
about. We just don't see it much.
That is interesting.
Millions of people are on statins now and I don't
know when the last case of hepatic toxicity that I have
heard about or read about occurred.
One of the other things I think about is exercise. Can
you do too much exercise? How do you know when too
much is too much?
When you start hurting yourself, when you start tear-
ing your tendons and muscles, you are doing too much
exercise.
The hardest thing for me to do is maintain anything.
Yes.
/ could lose weight, but I can't maintain. I could
exercise if I am continually competing with myself.
You know, it seems like the maximum benefit that
you can get from exercise in terms of health and life
span extension, etc., is 4-6 hours a week of moderately
vigorous exercise. Beyond that you may get stronger,
you may become more competitive, but there is no evi-
dence that you are improving your risk of avoiding
heart disease or dying.
What does moderate mean?
Well, I can't really give it to you in mets or calories,
but what it means is swimming at a reasonable pace or
jogging. Not running so hard that you get a stitch in
your side, but jogging 2-3 miles over a period of 45
minutes or 50 minutes. That is moderate. Once you try
to do more than a 10-minute mile you are probably
pushing it, and there are of course people who are tal-
ented athletes that can do that easily. But a ten-minute
mile, that is 6 miles an hour. If you go beyond that you
are probably beyond "moderate."
But if you do one mile would you want to do two or
three miles?
Yes. I am 58. I can run four 10-minute miles.
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/ can't.
If I try to get beyond that...
And that is probably more than you would need to
do. You answered my question, regarding the word
moderate. People say moderate but it means different
things. Therefore moderate may be idiosyncratic to the
individual. Like the 10-minute mile for some people may
be really...
Well, moderate performance goes down as you get
older. I don't expect to be able to do that 10-minute
mile easily 10 years from now. It would be nice, but I'd
be surprised. You really need to work with a trainer-—an
exercise physiologist—to get a sense of what is appro-
priate for you. And there are tables, etc. I am not an
exercise specialist. In fact, we just hired a really good
young scientist with a Ph.D. in exercise physiology to
help us with our exercise program.
Exercise has really become a science in the last few
years. Our body ages at different rates. Would there be
differential effects on different organs, such as the brain?
Yes, well, there is no evidence, for example, that diet
or exercise will help prevent Alzheimer's disease. We
can talk about some of the things that do seem to help
with that disease, but that is a nut that we are really
going to have to crack, because it is a serious problem.
And the incidence tends to go up very steeply as people
get into extreme old age. The incidence of Alzheimer's
degeneration gets very high, affecting perhaps 20-30%
of the population over 85. And we still don't know how
to prevent that. Estrogens seem to help and there are
some drugs out there which may also help a little, but
Alzheimer's is a big problem and we still don't com-
pletely understand it.
There are some drugs on the market or in develop-
ment that will supposedly help either reverse or slow
Alzheimer's down.
Slow it down, yes.
They also use the word reverse.
I don't see any evidence yet.
Do the scientists researching Alzheimer's Disease
know anything about how to slow down the aging
process?
Well no, Alzheimer's Disease is not an natural aging
in the sense that it happens to everyone. It is a disease.
If you don't have the tendency to get it you probably
won't. There probably are—in fact we know there are—
important genes that increase your risk of A.D. We are
identifying some of them. If you don't have any of
those genes, you probably won't get Alzheimer's. There
are people that have lived to 120 and didn't get Alz-
heimer's. They are aging, but they don't get Alzheimer's.
In other words, the percentage of people that get
Alzheimer's is different for different age groups. Of
course, we can get A.D. while young, but it is really a
function of age. As we get older we are more likely to get
it. There seems to be an order to that.
Yes, the age-related diseases all look like that though.
If you look at overall rates of cancer or heart disease,
etc. you'd see the same phenomenon. The difference
between aging and age-related disease is confusing to
people. Aging is a background process which is going
on all the time, which makes us increasingly vulnerable
to whatever age-related diseases we happen to have a
propensity for. If you have the genes that lead to a high
risk for heart disease, you probably are not going to get
it at 25 or 30, but you may get it at 45 or 50. So, it is an
age-related disease. If you have somewhat better genes
or dietary habits, or a combination thereof, you might
not get your heart disease until you are 75 or 80. If you
are really careful about diet and exercise and you have
just the right genes, you may never get coronary disease
at all. So heart disease is an age-related disease in the
sense that aging, or age, is one of the vulnerability factors
that determines when the disease will express itself
clinically. That is also true for Alzheimer's disease. It is
also true for cancers, etc. But they are all diseases. Type
II diabetes is another example. There are a whole var-
iety of factors which affect vulnerability to age-related
disease and age itself is just one of them. Your particular
genetics, your body weight, how much you exercise—
all will affect the likelihood that you will get diabetes at
any particular age. But age itself is also a factor. Very few
people get Type II diabetes in their 20s. Lots of people
get it in their 50s. But diabetes isn't aging, it is diabetes.
So, what we talked about earlier—caloric intake,
antioxidants—may be slowing down the aging process,
but also slowing down the disease process?
It won't slow down the disease process. But if you
slow down the aging process—if you set your biology
to the point where at 60 you are really more like a 40
year old—then your probability of getting an age-
related disease would be the probability of a 40 year
old and not the probability of a 60 year old. Think of
aging as the background—the field—upon which the
events are occurring.
There seems to be an increase in Alzheimer's and
senile dementia...If the life span is extended, can we
expect to see more of this? You extend life, but these are
diseases. Would this necessarily be the case?
Right. If we extend the life span so that a 100-year-
old person has the physiology (this would be the amount
of accumulative damage of all kinds) of a 50-year-old
person, then they would have the probability of a 50-
year-old person getting Alzheimer's disease.
/ have been confused about age-related diseases but
you just clarified it.
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Almost everybody does. Lots of scientists and doc-
tors do. I read articles all the time in learned medical
journals that make the same error. So you are in good
company.
/ should have known better. Since body parts and
organs do not seem to age at the same rate, what are
the implications of increased longevity for society? The
basic one is ...
Standing room only.
The medical costs?
Well, the medical costs shouldn't go up, because if
you actually extend the life span and decrease the rate
at which age-related diseases are occurring (chronic dis-
eases of aging, etc.), the medical costs should go down.
If people live longer, other things will go... Their parts
wear out, their joints...
I think that is all part of the aging process. It isn't just
wear and tear. Cartilage is not like the material on this
table—dead and incapable of repairing itself. Cartilage
has the capacity to repair itself. And the reason that not
everybody gets osteoarthritis as they get older is that
some people repair it better than others. Young cartilage
repairs itself quite well. The ability to repair the little
damage that we do to our joints every day by walking,
running, falling, decreases with age. So, eventually, some
people—even a lot of people—get osteoarthritis. The
cartilage gradually loses its capacity to repair itself and
begins to wear out. It gets bare spots where bone meets
bone. But that is not just wear and tear. Osteoarthritis is
a disease. It isn't just aging.
They are talking about now building cartilage and
other things. They are doing that.
They are starting that. I was at a really interesting
meeting a couple of weeks ago in San Francisco. I got
invited to give a talk at the American Academy of
Orthopedic Surgery and I went to a couple of their
meetings on this exact subject, which is using stem cells
to grow new cartilage. I could say that within ten years
we will be able to grow a new joint surface.
Are there any theories of aging that you think are
most valuable? Is there a particular biological theory
that you support? I think you indicated some biological
theories...
The major theories are the oxidative damage theory
(the oxidative stress which we talked about) and the
telomere hypothesis, which explains the Hayflick phe-
nomenon. There has been a genetic hypothesis. That is,
your rate of aging is simply determined by your genes—
genes somehow are timekeepers that set the aging
process. Our genes kill us, so to speak. I think that you
have to turn that one on its head. It would be more
accurate to say that we have genes which help us to
resist the aging process and, depending on how good
or bad they are, we age at different rates. The question
you might well ask is, "Why don't we have genes that are
much better than they are, so that we would live to be
250?" The answer appears to be because there has never
been an evolutionary reason why human beings needed
to live to 250. The evolutionary process has not selected
such genes for us. If survival of our species over the
next million years depended on having some 250-year-
old people, we would probably develop those genes.
/ am going to change the focus on you and try to get
more personal. What do you believe is the important
contribution that you have made?
I don't think that I have made any really important
contributions.
Moreover, when it comes to contributions of any
kind, I also think that I shouldn't say "I" because I have
always worked with a team. Marc Blackman and I have
had a wonderful long-term relationship. Dr. Blackman
was a Professor of Endocrinology and Medicine at Johns
Hopkins and has just become the Director of the NIH
Center for Complementary and Alternative Medicine.
Also, I have had good mentors. Dr. Blackman and I
have had great postdoctoral fellows work with us and
the research has always been a team effort. So, what I
should say is, we—my group, my section.. .people I have
worked with—I think we have helped elucidate some of
the hormonal changes that occur with aging. We have
shown that replacing hormones in older people who are
hormone deficient due to the aging process has some
potential benefits, which may be worth exploring further.
There is also potential for adverse effects. We need to
better understand how to reduce the adverse effects and
improve the beneficial effects. But our work has shown
that there are potential benefits and that it would be
worth the effort to try and optimize the risk/benefit ratio.
This is probably the limit of our contribution to date.
It sounds as though a greater understanding of hor-
monal changes associated with the aging process has
become a research priority.
I think that is part of it. We'd like to understand this
better and I am actually involved in some experiments
right now with some wonderful collaborators, to start
looking at this issue with regard to testosterone. I hope
to get back and look at growth hormone again, once we
have some better ways of dealing with growth hor-
mones. But my responsibility now as director of the
Kronos Institute is much broader. I have to look at a wider
variety of issues than just hormones and so we are look-
ing at how to get a better measure of oxidative stress so
that we can start looking at these new interventions to
reduce oxidative stress. We believe that this is one of the
major and important factors that underlies aging.
How does the Kronos Institute support these efforts?
The Kronos Institute—our mission is to do what is
called translational research. That is, we are not trying to
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do basic research to understand the aging process. We
don't work with cells, we don't work with animals. We
are doing human studies and (because these are things
that are doable in humans at this point) we are trying to
explore better ways of detecting the risks and of pre-
venting age-related disease. So, I think we have to first
detect the risks for age-related disease. Second, prevent
age-related disease. Then, our third mission is to test
(when they become available) novel measures for ex-
tending the maximum human life span potential. So far
there are no such measures (in my opinion) that are
ready for human testing. But, I think that there will be
within the next five years.
Previously, you mentioned possible tests for use in
the detection of age-related disease.
We want to detect and we want to prevent age-
related disease. That is it. Not everyone has the same
risks. One person's big risk may be osteoporosis, while
another person's may be cancer. We'd like to know
what your particular vulnerabilities are and we need
better algorithms to do that. We need things we can
measure, which will give us a better indication (whether
you are 40 years old or 50 years old) of which track you
are on, so we can change that track to a healthier one.
If you were to give me the goals of the Kronos Insti-
tute, would they be what you just said?
Yes. Translational research. Translational means
getting stuff from the basic lab into the clinical arena—
translating new information that is learned in cells,
animals, genes, whatever, into something that we can
use in people. So, our goals are to take new interven-
tions that are suggested by data coming out of the basic
research lab, that look like they are ready for human
application, and getting them quickly into clinical trials
to find out if they work. Our goal is within that
paradigm—there are better detection methods, better
preventions, and (finally) true life span extension
studies, which I think are blue sky at the moment.
Is it unique that the Kronos Institute is pursuing these
goals?
I don't know about unique, but I think that there
aren't very many people that are taking on this kind of
research. It hasn't been well supported. Frankly, I feel
that the National Institute on Aging is not doing the job
that Congress put it together to do. They are concentrat-
ing on age-related disease and they have also gotten a
lot of good basic research done, but they are not doing
a very good job of moving the information from the
research lab into the clinical arena. What I see the Kronos
Institute doing is moving faster, because our funding is
in place and our people will be in place, our laboratory
facilities are in place and our clinical facilities will be
in place...So, we can jump on something new and do
small studies, with 30 or 40 people, to test whether a
particular intervention looks really promising. Then, if
it does pan out, this will leverage major support, NIA
funds, drug company funds, big foundation funds, to do
the larger studies needed for final proof or rejection of
a new intervention.
Okay, you just answered another question I have, and
that is, can you be moving too fast? One of the criticisms
for and against this type of research is the federal regula-
tion of drugs. It takes too long to get them on the market
so people go to foreign countries to pick up drugs. And the
other argument is that when we do put something on the
market that has a negative effect ten years down the line,
maybe they will say, "Why didn't you detect it?"
I think it is possible to do things prematurely. Certainly
you don't want to start testing something on people
until you show that it is really non-toxic in animals. And
you don't want to approve something that you are
testing in people until you have really shown that it
doesn't hurt people in the long run.
But some of these things cause genetic damage. Well,
not genetic... DNA, but...
And that's always a risk. Some drugs have failed
even after being marketed. There are screens for things
that damage DNA, though...There are ways of measuring
DNA damage in vitro where you can learn if a drug is
really something that causes mutations. There are sys-
tems for detecting that. The toxicology screen that all
new drugs go through now includes testing for muta-
genicity. But, you are right in the larger sense and that
is that the long-term outcomes sometimes require what
are called Phase IV studies. That is, they have approved
the drug and then they watch large populations who
are treated for long periods of time and things emerge
that you simply didn't expect.
In this country, we have a huge number of people
who have been diagnosed with multiple personality
disorder. In other countries there is no such diagnosis
or illness. Some psychiatrists would say the behaviors
exist only because we have the diagnosis. In this country
we have a diagnosis, we have a theory for it, and some
of the diagnoses and detections of this seem to contain
the very nature of what we are looking for.
You are talking about detection bias. The same thing
is true of diabetes. We can create an epidemic of dia-
betes by improving our public relations and publicizing
the fact that people should come in and get their blood
sugars measured. So, you suddenly see a huge number
of new diabetics, because you have gotten people to
come in to get their blood sugars measured. Otherwise,
they would not be diagnosed.
And there is also a change in the acceptable blood
sugar level. It was 120, now it is 110. That has created
some additional confusion.
That's right.
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Where is the leading edge of aging research now? Do
we have adequate research leadership?
There are a lot of good people doing gerontology.
There is some very interesting stuff going on. It is hard
to name them all. There are probably 10-15 real leaders
in understanding the mechanisms of the aging process.
There is nobody that I can think of right now doing
clinical research on the prevention of aging. I think the
big advances will come from better antioxidants, ways
of mobilizing the repair mechanisms, and better under-
standing of mitochondrial processes (which may lead
to ways of stabilizing the mitochondria or getting rid of
old mitochondria so that the rate of oxidative damage
will be reduced). There is a lot of potential there and
I think the next five years is going to be very exciting.
/ am not sure if it is even meaningful to ask this last
question... But if you were in charge of funding certain
areas, what research areas would you fund? What
would hold the most promise for understanding the
process of aging and understanding the quality of life?
Mitochondrial research, oxidative stress research, DNA
repair research, and understanding which genes are turned
on and off in various systems during the aging process
and caloric restriction. Genetic research, too...
Everything that you have said dealt with the biology
of aging.
Yes.
And never dealt with quality of life. In fact, ...
I have no expertise in quality of life issues. I think
staying interested in things, exercising regularly and
eating a nutritious diet and loving people is going to
produce a good quality of life.
Are there any data ...?
Yes, there is associative data, but you don't know
what's the cart and what's the horse. If people are old
and hurting because of biological changes it is hard to
have a good quality of life. I think the psychological
research in aging shows that people as they get older
tend to become "more themselves." People don't really
change as they get older but display whatever char-
acteristics they had—if they are kind, they get kinder; if
they are mean, they get meaner...
That's the truth. Recently, a physician wrote a hook
entitled Doctor's Prescription: Go Fishing. The author
practices medicine at a cancer institute, where he has
trained patients to relax. He feels that this has helped
patients with their cancer. I don't know if they've sur-
vived any longer, but they may have had a nicer life
during the time they did survive...
Thank you Mitch. It was a pleasure.
